Acarix AB (publ) Logo

Acarix AB (publ)

ACARIX.ST

(1.5)
Stock Price

0,32 SEK

-103.3% ROA

-121.56% ROE

-3.79x PER

Market Cap.

306.548.550,00 SEK

0% DER

0% Yield

-1133.87% NPM

Acarix AB (publ) Stock Analysis

Acarix AB (publ) Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Acarix AB (publ) Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

2 Revenue Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

3 PBV

The stock's PBV ratio (2.25x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

4 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

5 ROE

Negative ROE (-131.45%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

6 ROA

The stock's ROA (-188.34%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Acarix AB (publ) Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Acarix AB (publ) Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Acarix AB (publ) Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Acarix AB (publ) Revenue
Year Revenue Growth
2014 0
2015 0 0%
2016 0 0%
2017 638.000 100%
2018 1.024.000 37.7%
2019 1.857.000 44.86%
2020 2.170.000 14.42%
2021 3.760.000 42.29%
2022 5.822.000 35.42%
2023 6.292.000 7.47%
2023 6.241.000 -0.82%
2024 7.832.000 20.31%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Acarix AB (publ) Research and Development Expenses
Year Research and Development Expenses Growth
2014 18.900.000
2015 8.674.000 -117.89%
2016 1.247.000 -595.59%
2017 5.289.000 76.42%
2018 12.344.000 57.15%
2019 20.282.000 39.14%
2020 14.469.000 -40.18%
2021 21.493.000 32.68%
2022 27.758.000 22.57%
2023 25.588.000 -8.48%
2023 28.516.000 10.27%
2024 22.068.000 -29.22%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Acarix AB (publ) General and Administrative Expenses
Year General and Administrative Expenses Growth
2014 0
2015 6.703.000 100%
2016 25.543.000 73.76%
2017 25.884.000 1.32%
2018 30.887.000 16.2%
2019 27.591.000 -11.95%
2020 28.556.000 3.38%
2021 33.026.000 13.53%
2022 53.338.000 38.08%
2023 48.480.000 -10.02%
2023 54.334.000 10.77%
2024 51.404.000 -5.7%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Acarix AB (publ) EBITDA
Year EBITDA Growth
2014 -23.831.000
2015 -15.248.000 -56.29%
2016 -49.602.000 69.26%
2017 -29.180.000 -69.99%
2018 -39.722.000 26.54%
2019 -42.263.000 6.01%
2020 -37.991.000 -11.24%
2021 -48.282.000 21.31%
2022 -73.785.000 34.56%
2023 -65.664.000 -12.37%
2023 -76.979.000 14.7%
2024 -63.416.000 -21.39%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Acarix AB (publ) Gross Profit
Year Gross Profit Growth
2014 -18.900.000
2015 -8.674.000 -117.89%
2016 0 0%
2017 430.000 100%
2018 708.000 39.27%
2019 1.430.000 50.49%
2020 1.594.000 10.29%
2021 2.823.000 43.54%
2022 4.621.000 38.91%
2023 5.168.000 10.58%
2023 5.297.000 2.44%
2024 4.256.000 -24.46%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Acarix AB (publ) Net Profit
Year Net Profit Growth
2014 -19.209.000
2015 -12.393.000 -55%
2016 -48.240.000 74.31%
2017 -29.776.000 -62.01%
2018 -42.271.000 29.56%
2019 -46.459.000 9.01%
2020 -41.548.000 -11.82%
2021 -51.802.000 19.79%
2022 -77.495.000 33.15%
2023 -69.164.000 -12.05%
2023 -77.839.000 11.14%
2024 -66.644.000 -16.8%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Acarix AB (publ) Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2014 -1
2015 -1 0%
2016 -2 100%
2017 -1 0%
2018 -1 100%
2019 -1 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Acarix AB (publ) Free Cashflow
Year Free Cashflow Growth
2014 -21.681.000
2015 -15.151.000 -43.1%
2016 -21.257.000 28.72%
2017 -43.523.000 51.16%
2018 -38.609.000 -12.73%
2019 -44.533.000 13.3%
2020 -36.686.000 -21.39%
2021 -48.050.000 23.65%
2022 -75.020.000 35.95%
2023 -16.721.000 -348.66%
2023 -81.367.000 79.45%
2024 -15.242.000 -433.83%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Acarix AB (publ) Operating Cashflow
Year Operating Cashflow Growth
2014 -20.871.000
2015 -8.631.000 -141.81%
2016 -9.056.000 4.69%
2017 -40.539.000 77.66%
2018 -38.609.000 -5%
2019 -44.533.000 13.3%
2020 -36.686.000 -21.39%
2021 -48.007.000 23.58%
2022 -74.869.000 35.88%
2023 -16.721.000 -347.75%
2023 -81.367.000 79.45%
2024 -15.259.000 -433.24%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Acarix AB (publ) Capital Expenditure
Year Capital Expenditure Growth
2014 810.000
2015 6.520.000 87.58%
2016 12.201.000 46.56%
2017 2.984.000 -308.88%
2018 0 0%
2019 0 0%
2020 0 0%
2021 43.000 100%
2022 151.000 71.52%
2023 0 0%
2023 0 0%
2024 -17.000 100%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Acarix AB (publ) Equity
Year Equity Growth
2014 15.123.000
2015 12.139.000 -24.58%
2016 155.516.000 92.19%
2017 128.939.000 -20.61%
2018 87.877.000 -46.73%
2019 76.604.000 -14.72%
2020 82.136.000 6.74%
2021 100.544.000 18.31%
2022 51.825.000 -94.01%
2023 51.885.000 0.12%
2023 29.072.000 -78.47%
2024 67.807.000 57.13%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Acarix AB (publ) Assets
Year Assets Growth
2014 18.284.000
2015 15.582.000 -17.34%
2016 173.286.000 91.01%
2017 134.056.000 -29.26%
2018 95.197.000 -40.82%
2019 82.983.000 -14.72%
2020 89.948.000 7.74%
2021 118.601.000 24.16%
2022 69.481.000 -70.7%
2023 62.884.000 -10.49%
2023 38.457.000 -63.52%
2024 79.618.000 51.7%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Acarix AB (publ) Liabilities
Year Liabilities Growth
2014 3.161.000
2015 3.443.000 8.19%
2016 17.770.000 80.62%
2017 5.117.000 -247.27%
2018 7.320.000 30.1%
2019 6.379.000 -14.75%
2020 7.812.000 18.34%
2021 18.057.000 56.74%
2022 17.656.000 -2.27%
2023 10.998.000 -60.54%
2023 9.385.000 -17.19%
2024 11.811.000 20.54%

Acarix AB (publ) Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.01
Net Income per Share
-0.08
Price to Earning Ratio
-3.79x
Price To Sales Ratio
48.99x
POCF Ratio
-3.67
PFCF Ratio
-4.18
Price to Book Ratio
3.96
EV to Sales
41.28
EV Over EBITDA
-3.74
EV to Operating CashFlow
-3.53
EV to FreeCashFlow
-3.52
Earnings Yield
-0.26
FreeCashFlow Yield
-0.24
Market Cap
0,31 Bil.
Enterprise Value
0,26 Bil.
Graham Number
0.39
Graham NetNet
0.06

Income Statement Metrics

Net Income per Share
-0.08
Income Quality
1.03
ROE
-1.22
Return On Assets
-0.89
Return On Capital Employed
-1.04
Net Income per EBT
1
EBT Per Ebit
1
Ebit per Revenue
-11.3
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
8.27
Research & Developement to Revenue
3.92
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.77
Operating Profit Margin
-11.3
Pretax Profit Margin
-11.34
Net Profit Margin
-11.34

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.09
Free CashFlow per Share
-0.09
Capex to Operating CashFlow
-0
Capex to Revenue
0.02
Capex to Depreciation
0.08
Return on Invested Capital
-1.04
Return on Tangible Assets
-1.03
Days Sales Outstanding
776.73
Days Payables Outstanding
618.42
Days of Inventory on Hand
1496.02
Receivables Turnover
0.47
Payables Turnover
0.59
Inventory Turnover
0.24
Capex per Share
0

Balance Sheet

Cash per Share
0,06
Book Value per Share
0,08
Tangible Book Value per Share
0.07
Shareholders Equity per Share
0.08
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.7
Current Ratio
5.72
Tangible Asset Value
0,06 Bil.
Net Current Asset Value
0,06 Bil.
Invested Capital
66887000
Working Capital
0,06 Bil.
Intangibles to Total Assets
0.14
Average Receivables
0,01 Bil.
Average Payables
0,00 Bil.
Average Inventory
6484500
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Acarix AB (publ) Dividends
Year Dividends Growth

Acarix AB (publ) Profile

About Acarix AB (publ)

Acarix AB (publ), a medical technology company, develops and commercializes diagnostic tests for cardiovascular diseases in Germany, Sweden, the Middle East, Switzerland, Austria, and internationally. The company offers CADScor System, a non-invasive and ultra-sensitive analytical device for the diagnosis of coronary artery disease. Acarix AB (publ) was founded in 2009 and is headquartered in Malmö, Sweden.

CEO
Mr. Aamir Mahmood
Employee
14
Address
Jungmansgatan 12
Malmö, 211 19

Acarix AB (publ) Executives & BODs

Acarix AB (publ) Executives & BODs
# Name Age
1 Mr. Jeff Thomas
Head of US Sales
70
2 Mr. Aamir Mahmood
President & Chief Executive Officer
70
3 Mr. Christian Lindholm
Chief Financial Officer & Executive Vice President
70
4 Ms. Jennifer Matson
Head of Medical Affairs
70
5 Ms. Carma Connely
Head of Market Access & Customer Excellence
70
6 Mr. Thomas Borch
Interim Chief Operating Officer
70
7 Dr. Claus Bo Vöge Christensen
Founder and Interim Head of R&D
70

Acarix AB (publ) Competitors

Saniona AB (publ) Logo
Saniona AB (publ)

SANION.ST

(0.8)
Cantargia AB (publ) Logo
Cantargia AB (publ)

CANTA.ST

(1.5)
AegirBio AB (publ) Logo
AegirBio AB (publ)

AEGIR.ST

(1.2)